6 news items
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
STIM
15 May 24
that Humana has become the first commercial payer to update its policy in response to the Company's recent clearance from the U.S. Food and Drug
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results
STIM
7 May 24
certain standards of patient care and responsiveness developed in collaboration with medical experts. Regardless of practice size or tenure
Neuronetics, Inc. Announces New Publication In Brain Stimulation Confirms Full TMS Treatment Course Is Vital
STIM
10 Apr 24
symptom improvement in major depressive disorder (MDD) is strongly predictive of response at the completion of transcranial magnetic stimulation (TMS
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
STIM
10 Apr 24
concludes that while early symptom improvement in major depressive disorder (MDD) is strongly predictive of response at the completion of transcranial
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
STIM
25 Mar 24
first-line treatment for adolescents, backed by real-world data and impressive response rates consistent with response rates for adults
n2ovkex6 dn
STIM
5 Mar 24
certain standards of patient care and responsiveness developed in collaboration with medical experts. Regardless of practice size or tenure, this program
- Prev
- 1
- Next